Purpose
To evaluate in a prospective randomized study the long-term results of adjuvant locoregional chemoimmunotherapy in a number of patients with stage III pancreatic duct cancer who underwent pancreatic resection between November 1993 and October 2000.
Methods
One hundred twenty-eight patients were divided into three groups.
Group A (n ϭ 40) patients had surgical resection alone. Group B (n ϭ 45) patients had, using a side arterial branch of the jejunal artery, an arterial catheter advanced under fluoroscopic control into the superior mesenteric artery. Group B patients also received adjuvant chemotherapy. Group C (n ϭ 43) patients had the same kind of arterial catheter and received as an adjuvant treatment locoregional chemoimmunotherapy.
During the initial surgical exploration, all patients underwent pancreatic resection. Pancreatic resection involved a standard technique of extended duodenopancreatectomy with regional lymphadenectomy and was carried out in all patients by the first author. At the end of intervention, all patients were randomly assigned to the above-mentioned groups. Randomization was based mainly on histologic evidence of the stage of the disease.
Results
The 2-and 5-year survival rates were 29% and 0% for group A, 52% and 10% for group B, and 65% and 18% for group C. The respective percentages for disease-free survival were 20% and 0% for group A, 35% and 7% for group B, and 58% and 11% for group C. Since statistical differences among groups were observed from the second and third years, the study was interrupted early for ethical reasons.
Conclusions
When applied regionally, combined chemoimmunotherapy is simple, safe, and effective. This type of therapy offers substantial advantages in terms of prolonging overall survival and improving disease-free survival compared to surgical resection alone or to surgical resection and adjuvant regional chemotherapy.
Surgical resection remains the gold standard for the management of pancreatic cancer. [1] [2] [3] However, despite impressive improvements on early results concerning hospital mortality and morbidity, long-term results regarding overall survival remain disappointingly poor, particularly for patients with stage 3 disease who are undergoing surgical resection. 4 This dismal figure is even more distressing if we consider that 90% of the patients at diagnosis have stage 3 or 4 disease. The present study is a prospective randomized study assessing long-term results in 128 of 214 consecutive patients who underwent pancreatic resection in Athens, Greece, between November 1993 and October 2000 for stage 3 pancreatic duct carcinoma.
METHODS
To be enrolled in this study, patients had to meet the criteria for stage 3 pancreatic duct carcinoma as this was based on diagnostic screening and mainly on histologic confirmation of resected specimens. All patients signed an informed consent, which was approved by our hospital ethics committee.
Patients were excluded from the study if they: 1. Did not agree to participate and did not sign the relevant consent 2. Were found to have stage 1 or 2 disease 3. Underwent total pancreatectomy 4. Were found to have arterial vascular involvement (hepatic artery, superior mesenteric artery) 5. Underwent regional vascular resection reconstruction (of either the portal or superior mesenteric vein) 6. Were found during either screening or at initial exploration to have liver secondaries, peritoneal dissemination, ascites, or lung or bone metastases.
Randomization was carried out in all patients at the end of operative procedure to optimize intraoperative staging and to include patients with similar mechanical and anatomic peculiarities. Special emphasis was given to items such as the histologic evaluation via frozen biopsies of the resected specimen, the presence of lymph node involvement, and the presence of residual pathology in the pancreatic remnant. At the end of intervention and after the pathology report, the anesthesiologist assigned each patient into one of three groups according to the chosen sealed envelope.
Before closing the abdomen, patients in groups B and C had an arterial catheter introduced via a side arterial branch through the jejunal artery under fluoroscopic control into the superior mesenteric artery (SMA) to receive their adjuvant treatment. If this was not technically feasible, the catheter was inserted into the SMA postoperatively in the department of radiology through the left subclavian artery under ultrasound guidance ( Fig. 1 ). Arterial catheters (provided by PFM manufacturer), were 4F (OD) and made of polyure-thane, with a guide wire to facilitate their advancement and positioning into the SMA. To maintain patency of the catheters, infusion of 10 mL normal saline 0.9% with 1 mL heparin was given every 2 weeks during the time patients were not undergoing treatment.
The patients included in the therapeutic protocol were assigned randomly to three groups. Group A had pancreatic resection alone. Group B had pancreatic resection supplemented with regional targeting chemotherapy.
Group C had pancreatic resection supplemented with regional targeting chemoimmunotherapy.
The demographic and epidemiologic characteristics of the patients are shown in Table 1 . After the initial admission, all patients underwent standard screening tests including blood tests, chest x-rays, upper abdominal computed tomography, and magnetic resonance angiography to delineate regional anatomy and to define existing anatomic and mechanical peculiarities of the regional vascular structures (Figs. 2 and 3).
Twenty days following surgery, group B and group C patients had a 5-day course of chemotherapy. The chemotherapy regimen was as follows: Advanced Pancreatic Cancer Group C continued with a 10-day course of regional immunotherapy using 1 mL interleukin-2, 18 ϫ 10 6 IU, suspended in 1 mL Lipiodol and 0.5 mL Urografin 58% given as a bolus injection via the SMA catheter. Adjuvant treatment (chemotherapy or immunoterapy) was carried out for the first year every 2 months, for the second and third years every 4 months, and for the fourth and fifth years every 6 months. Blood screening tests were carried out before each cycle of treatment. Upper abdominal computed tomography, chest x-rays, and serum CA 19-9 levels were evaluated every 3 months for the first and second years and every 6 months for the subsequent years ( Table 2) .
Resected specimens were histologically and immunohistochemically evaluated, confirming the validity of our sample selection.
Overall survival and overall disease-free survival were analyzed from the date of pancreatic resection to the date of death (for overall survival) or to the date of regional recurrence or systemic spread (for disease-free survival). Overall survival and disease-free survival for the entire follow-up period (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) were estimated according to the Kaplan-Meier method and compared using the Cox-Mantel test. Comparisons of the incidence of locoregional recurrence and the incidence of secondary metastatic liver disease among groups were calculated with the chi-square test. Statistical analysis was done with Statistica software; P Ͻ .05 was considered to indicate statistical significance.
RESULTS
Of the 214 initial patients, the following were excluded: 7 did not agree to participate and did not sign consent; 15 were found to have stage 1 or 2 disease according to the pathology report; 4 underwent total pancreatectomy; 12 were found to have arterial vascular involvement (hepatic artery, SMA); 4 had regional vascular reconstruction; 28 were found during screening to have liver secondaries (n ϭ 15), peritoneal dissemination with ascites (n ϭ 10), or lung (n ϭ 5) or bone metastases (n ϭ 3); 8 had advanced-stage disease during initial exploration (peritoneal seeding, n ϭ 6; liver metastases, n ϭ 2); and 4 had positive resectional margins. The remaining 131 patients were included in this study. Group A (n ϭ 41) patients had pancreatic resection alone, group B (n ϭ 46) patients had pancreatic resection supplemented with regional targeting chemotherapy, and group C (n ϭ 44) patients had pancreatic resection supplemented with regional targeting chemoimmunotherapy.
In 12 patients (5 in group B, 7 in group C) the catheter was inserted into the SMA postoperatively in the department of radiology through the left subclavian artery under ultrasound guidance, since this was not technically feasible during surgery.
Three patients died during the first 30 days following pancreatic resection and were excluded from this study. Deaths were secondary to the operative procedure and were not related to the adjuvant treatment. One death occurred in each group.
Morbidity was easily controlled, and only two patients underwent reoperation for bleeding (Table 3) .
Treatment-related toxicity was minimal (Table 4) : leuko-penia, anemia, thrombocytopenia, nausea, and vomiting were seen in 9.3%, 12.8%, 4.7%, 9.3%, and 10.5%, respectively. Ninety percent of group C patients had fever and all group C patients had chills; both were easily controlled with paracetamol administration. Complications from the catheters and subcutaneous pumps were seen in six patients. In two of them, treatment was interrupted and the catheters were removed. In the remaining four patients, the catheters were removed and new ones were introduced via the subclavian artery via angiography into the SMA. Two patients in whom the arterial catheters were removed and not replaced are included in this study. (One was assigned to group B and the other to group C during the randomization process.) Thus, the final number of patients per group was as follows: group A, n ϭ 40; group B, n ϭ 45; group C, n ϭ 43.
Survival for group A (Table 5 ) patients ranged from 11 to 41 months (mean 18.8 Ϯ 11.7). Disease-free survival for group A patients ranged from 7 to 39 months (mean 14.2 Ϯ 9.6). One-, 2-, 3-, and 4-year survival rates were 65.0%, 29%, 15%, and 0%, respectively ( Table 6 ). One-, 2-, 3-, and Leukopenia  4  2  1  1  --4  2  1  1  --Anemia  6  2  2  2  --5  1  2  2  --Thrombocytopenia  2  -1  1  --2  -2  ---Vomiting  4  -2  2  --4  --2  2  -Nausea  5  1  -3  1  -4  1  1  2 -- For group B patients, survival ranged from 12 to 51 months (mean 25 Ϯ 15.7) and disease-free survival ranged from 10 to 44 months (mean 21.7 Ϯ 15.5 months). One-, 2-, 3-, 4-, and 5-year survival rates were 72%, 53%, 31%, 16%, and 0%, respectively. One-, 2-, 3-, 4-, and 5-year disease-free survival rates were 62%, 35%, 22%, 0%, and 0%, respectively.
In Group C patients, survival ranged from 10 to 71 months (mean 31.07 Ϯ 17.31) and disease-free survival ranged from 10 to 54 months (mean 27.52 Ϯ 15.27). One-, 2-, 3-, 4-, and 5-year survival rates were 92%, 65%, 49%, 28%, and 18%, respectively. One-, 2-, 3-, 4-, and 5-year disease-free survival rates were 81%, 58%, 39%, 25%, and 0%, respectively. There was a statistically significant difference (Cox-Mantel test) concerning survival when comparing groups A and B (P ϭ .05), groups A and C (P ϭ .02), and groups B and C (P ϭ .02). There was also a statistically significant difference (Cox-Mantel test) concerning disease-free survival when comparing groups A and Group B (P ϭ .01), groups A and C (P ϭ .001), and groups B and C (P ϭ .03).
Two years after surgery, the incidence of locoregional recurrence, liver secondaries, and peritoneal spread was 64.4%, 60.3%, and 45%, respectively, in group A; 30%, 28%, and 30% in group B; and 15%, 12%, and 19% in group C ( Table 7 ). The odds ratio (Table 8 ) for locoregional recurrence concerning groups A and B was 4.429; that for groups B and C was 2.516; and that for groups A and C was 11.143. The odds ratio for liver secondaries concerning groups A and B was 4.000; that for groups B and C was 2.775; and that for groups A and C was 11.100. The odds ratio for peritoneal spread concerning groups A and B was 1.951; that for groups B and C was 1.782; and that for groups A and C was 3.477. All odds ratios greater than 3 were statistically different from 1, signifying a higher increase of risk for a group A patient.
DISCUSSION
This study provides evidence that locoregional targeting chemoimmunotherapy significantly increases survival for patients with advanced but resectable pancreatic head car- cinoma compared to patients who undergo standard regional duodenopancreatectomy alone and to those who have pancreatic resection supplemented with regional chemotherapy. Indeed, the locoregional application of chemotherapy, in the form of a 5-day course, combined with a 10-day course of immunotherapy, has been associated with satisfactory results in terms of long-term survival, quality of postoperative life, low incidence of locoregional recurrence, low incidence of metastatic liver disease, and low incidence of peritoneal seeding. When we compare patients in group A (pancreatic resection) with patients in group B (pancreatic resection plus adjuvant locoregional chemotherapy) and those in group C (pancreatic resection plus adjuvant chemoimmunotherapy), we may well accept that this type of approach is highly recommended for patients with advanced pancreatic carcinoma. Indeed, realizing that all patients presented in this study were seen with advanced-stage disease (stage III), we may well postulate that pancreatic resection combined with adjuvant locoregional chemoimmunotherapy represents the gold standard for patients with stage 3 pancreatic duct carcinoma. Have we enough objective elements to ensure the credibility of our results?
The present prospective randomized study was designed to define how we could prolong survival and improve the quality of postoperative life in patients undergoing resectional pancreatic surgery for histologically proven stage 3 pancreatic duct adenocarcinoma. Several factors made this study interesting and different from similar studies. First, it was a small, single-institution, well-controlled study. Second, we took care to include patients with identical anatomic and mechanical peculiarities in terms of the origin and stage of their disease based on purely histologic grounds. Third, we used a standard surgical technique, and one surgeon performed all the operative procedures in this study. 5 Fourth, we report our results 1 year after the end of this study using actual, not actuarial, figures.
We are well informed of recently published results regarding patient benefits secondary to adjuvant systemic chemotherapy and negative results, despite early enthusiasm, concerning adjuvant chemoradiotherapy. 6 -8 We were able to show clear evidence from our results that adjuvant locoregional chemoimmunotherapy, combined with surgical resection, offers a significant improvement in the overall survival rates and disease-free survival rates in patients with Advanced Pancreatic Cancer stage 3 pancreatic duct carcinoma. Stage 3 pancreatic cancer is associated with a mean overall survival no longer than 11 months after surgical resection and with a poor quality of life due to early recurrence. 4, 5 Not only is survival short, but also the quality of postoperative life is poor, marred by the high incidence of locoregional recurrence, peritoneal spread, and development of liver secondaries. 6 -8 Indeed, the incidence of overall recurrence (local, hepatic, peritoneal distant) ranges from 67% to 100% 1 to 2 years following surgical resection for pancreatic cancer. 9 -17 Many attempts have been made to improve this situation. 6 -8 Systemic chemotherapy, alone or in combination with regional radiotherapy, failed to offer substantially prolonged survival. 6, 7 It appears that standard doses of postoperative adjuvant chemoradiotherapy do not offer any survival advantage and may even be disadvantageous. 6 The aphorism, coming from one of most enthusiastic supporters of adjuvant chemoradiotherapy, is of great interest and justified those who never were convinced of the value of combined adjuvant treatment. 18 In contrast, regional chemotherapy has been shown to be associated with satisfactory results in terms of prolonged survival and disease-free survival. 5,7,8,16 -20 Our results show clearly that regional chemoimmunotherapy prolongs overall survival and disease-free survival and is associated with an impressively low 2-year overall recurrence rate. Our incidence of locoregional recurrence (15%), liver secondaries (19%), and peritoneal spread (12%) contrasts sharply with figures from other studies. 9 -15 What are the underlying reasons for these phenomena, and how objective was the design of this study in terms of the validity of our results?
Several factors may well be considered as major contributing factors. The administration of chemotherapy lasted 5 days and was given as a continuous 6-hour infusion via the SMA using a pump, ensuring a constant perfusion rate. It was followed by a 10-day regional administration via the same SMA catheter of interleukin-2 in the form of an emulsion in a mixture of Lipiodol and Urografin. This regimen is associated with promising results. The survival of group C patients, particularly the 5-year survival of 18% compared with 0% for group A and B patients, must be considered a step forward. The favorable outcome of this treatment is mirrored in our figures regarding locoregional recurrence, secondary metastatic liver disease, and peritoneal seeding at 2 years of follow-up. We attribute this phenomenon to locoregional administration of both chemotherapy and immunotherapy and more specifically to the administration of interleukin-2 via the SMA, which leads to the activation of both tumor-infiltrated lymphocytes confined to the pancreatic space occupied by the tumor and to the activation of Kupffer cells, Pitt cells, and macrophages that are harbored in the liver sinusoids. 5 In previous studies, we demonstrated that interleukin-2 in a Lipiodol-Urografin emulsion is entrapped in the pancreatic space occupied by the tumor, including droplets of 25 m that are retained in the vascular network of the organ space occupied by the tumor, involving mainly the tumor's newly developed vascular network. Further, the continuous 6-hour infusion of the chemotherapy into both the pancreas and the liver increases the effectiveness of the therapy against regional cancer cells. 5 Pancreatic carcinoma has several important peculiarities. First, it is associated with high tissue concentrations of multidrug-resistant genes, rendering the disease resistant to systemic chemotherapy. 16, 17, 21 Indeed, it is assumed that the regional delivery of chemotherapy agents, which are entrapped in the vascular network of the organ space occupied by the tumor, leads to a higher concentration of the drugs within the tumor, which is expected to improve the response rate regarding the extent of tumor necrosis in a way that could never be achieved using the systemic route of administration. [22] [23] [24] [25] [26] Moreover, tissue culture data showed that a significant improvement in terms of response for the majority of gastrointestinal tumors takes place only after increasing the drug dose to 5 to 10 times above the acceptable dose used for systemic administration of the drug. 16, 21 Such levels are highly toxic if used on a systemic level and can never be reached by a systemic route of administration. 16, 17 In a previous study, our policy of using 6-hour infusions of chemotherapy via the SMA route for 5 days was shown to result in significant tumor shrinkage and necrosis. 5 The combination of regional administration of interleukin-2 immediately after chemotherapy is highly effective.
It is postulated that regional chemotherapy affects cancer cells by inducing not only tumor necrosis but also an upregulation of their activity relevant to their ability to secrete a cascade of cytokines (e.g., transforming growth factor B1, interleukin-10, interleukin-6), by which a prominent inactivation of tumor infiltrating lymphocytes occurs. 24 Thus, it has been seen that anergy of tumor infiltrating lymphocytes, as it can be estimated by reduced surface marker expression like IL2 and HLA-DR expression, recovers when those cells are exposed to regional delivery of interleukin-2 secondary to regional administration of immunostimulants. 26 Practically, it is exactly the same phenomenon as that which occurs along the extracorporeal inoculation of tumor infiltrating lymphocytes with interleukin-2. 22 The combination of regional chemotherapy with immunotherapy offers ideal conditions for tumor necrosis and for more effective control of the disease. Ishikawa et al., with a number of studies, confirmed the superiority of adjuvant regional chemotherapy over adjuvant systemic chemotherapy and radiotherapy. 18 Similar results favoring regional adjuvant chemotherapy were reported by other authors as well. 16, 19, 20 In conclusion, we believe that the biggest advantage of regional chemoimmunotherapy over systemic chemoradiotherapy is that regional therapy is less toxic in terms of side effects and more effective in reducing the incidence of locoregional recurrences of malignant liver secondaries and the incidence of peritoneal seeding and thus in prolonging overall and disease-free survival.
